COVID-19-associated serum and cerebrospinal fluid cytokines in post- versus para-infectious SARS-CoV-2-related Guillain-Barré syndrome
© 2024. Fondazione Società Italiana di Neurologia..
INTRODUCTION: Guillain-Barré syndrome associated with Coronavirus-2-related severe acute respiratory syndrome (COV-GBS) occurs as para- or post-infectious forms, depending on the timing of disease onset. In these two forms, we aimed to compare the cerebrospinal fluid (CSF) and serum proinflammatory cytokine profiles to evaluate differences that could possibly have co-pathogenic relevance.
MATERIALS AND METHODS: We studied a retrospective cohort of 26 patients with either post-COV-GBS (n = 15), with disease onset occurring > 7 days after SARS-CoV-2 infection, or para-COV-GBS (n = 11), with disease onset 7 days or less. TNF-α, IL-6, and IL-8 were measured in the serum with SimplePlex™ Ella™ immunoassay. In addition to the para-/post-COV-GBS patients, serum levels of these cytokines were determined in those with non-COVID-associated-GBS (NC-GBS; n = 43), paucisymptomatic SARS-CoV-2 infection without GBS (COVID, n = 20), and in healthy volunteers (HV; n = 12). CSF cytokine levels were measured in patients with para-/post-COV-GBS, in those with NC-GBS (n = 29), or with Alzheimer's disease (AD; n = 24).
RESULTS: Serum/CSF cytokine levels did not differ in para- vs post-COV-GBS. We found that SARS-CoV-2 infection raises the serum levels of TNF-α, IL-6, and IL-8, as well as an increase of IL-6 (in serum and CSF) and IL-8 (in CSF) in either NC-GBS or COV-GBS than controls. CSF and serum cytokine levels resulted independent one with another.
CONCLUSIONS: The change of cytokines linked to SARS-CoV-2 in COV-GBS appears to be driven by viral infection, although it has unique characteristics in GBS as such and does not account for cases with para- or post-infectious onset.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology - 45(2024), 3 vom: 13. Feb., Seite 849-859 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Massa, Federico [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10072-023-07279-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366596373 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366596373 | ||
| 003 | DE-627 | ||
| 005 | 20240214233045.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10072-023-07279-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM366596373 | ||
| 035 | |a (NLM)38169013 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Massa, Federico |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19-associated serum and cerebrospinal fluid cytokines in post- versus para-infectious SARS-CoV-2-related Guillain-Barré syndrome |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. Fondazione Società Italiana di Neurologia. | ||
| 520 | |a INTRODUCTION: Guillain-Barré syndrome associated with Coronavirus-2-related severe acute respiratory syndrome (COV-GBS) occurs as para- or post-infectious forms, depending on the timing of disease onset. In these two forms, we aimed to compare the cerebrospinal fluid (CSF) and serum proinflammatory cytokine profiles to evaluate differences that could possibly have co-pathogenic relevance | ||
| 520 | |a MATERIALS AND METHODS: We studied a retrospective cohort of 26 patients with either post-COV-GBS (n = 15), with disease onset occurring > 7 days after SARS-CoV-2 infection, or para-COV-GBS (n = 11), with disease onset 7 days or less. TNF-α, IL-6, and IL-8 were measured in the serum with SimplePlex™ Ella™ immunoassay. In addition to the para-/post-COV-GBS patients, serum levels of these cytokines were determined in those with non-COVID-associated-GBS (NC-GBS; n = 43), paucisymptomatic SARS-CoV-2 infection without GBS (COVID, n = 20), and in healthy volunteers (HV; n = 12). CSF cytokine levels were measured in patients with para-/post-COV-GBS, in those with NC-GBS (n = 29), or with Alzheimer's disease (AD; n = 24) | ||
| 520 | |a RESULTS: Serum/CSF cytokine levels did not differ in para- vs post-COV-GBS. We found that SARS-CoV-2 infection raises the serum levels of TNF-α, IL-6, and IL-8, as well as an increase of IL-6 (in serum and CSF) and IL-8 (in CSF) in either NC-GBS or COV-GBS than controls. CSF and serum cytokine levels resulted independent one with another | ||
| 520 | |a CONCLUSIONS: The change of cytokines linked to SARS-CoV-2 in COV-GBS appears to be driven by viral infection, although it has unique characteristics in GBS as such and does not account for cases with para- or post-infectious onset | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Cytokines | |
| 650 | 4 | |a Guillain–Barré syndrome | |
| 650 | 4 | |a Neuroinflammation | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Interleukin-8 |2 NLM | |
| 700 | 1 | |a Vigo, Tiziana |e verfasserin |4 aut | |
| 700 | 1 | |a Bellucci, Margherita |e verfasserin |4 aut | |
| 700 | 1 | |a Giunti, Debora |e verfasserin |4 aut | |
| 700 | 1 | |a Emanuela, Maria Mobilia |e verfasserin |4 aut | |
| 700 | 1 | |a Visigalli, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Capodivento, Giovanna |e verfasserin |4 aut | |
| 700 | 1 | |a Cerne, Denise |e verfasserin |4 aut | |
| 700 | 1 | |a Assini, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Boni, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Rizzi, Domenica |e verfasserin |4 aut | |
| 700 | 1 | |a Narciso, Eleonora |e verfasserin |4 aut | |
| 700 | 1 | |a Grisanti, Giuseppe Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Coco, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Uccelli, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Schenone, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Franciotta, Diego |e verfasserin |4 aut | |
| 700 | 1 | |a Benedetti, Luana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology |d 2000 |g 45(2024), 3 vom: 13. Feb., Seite 849-859 |w (DE-627)NLM108608468 |x 1590-3478 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2024 |g number:3 |g day:13 |g month:02 |g pages:849-859 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10072-023-07279-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2024 |e 3 |b 13 |c 02 |h 849-859 | ||